Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPID | Q08752 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | CCKBR | P32239 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14066122 | 1.00 | PPID (0.45) | PPIDNPC1CCR1UBE2NTSHR | |
| SCHEMBL28491402 | 0.84 | PPID (0.46) | PPIDNPC1CCR1UBE2NTSHR | |
| SCHEMBL7713758 | 0.80 | SMN1; SMN2 (0.50) | KMT2AALDH1A1KDM4E | |
| SCHEMBL4863045 | 0.78 | TSHR (0.53) | PPIDNPC1CCR1UBE2NTSHR | |
| SCHEMBL14066124 | 0.78 | TSHR (0.53) | PPIDNPC1CCR1UBE2NTSHR | |
| SCHEMBL4860453 | 0.77 | PPID (0.40) | PPIDNPC1CCR1UBE2NTSHR | |
| SCHEMBL6013884 | 0.77 | PPID (0.40) | PPIDNPC1CCR1UBE2NTSHR | |
| SCHEMBL6013883 | 0.77 | PPID (0.40) | PPIDNPC1CCR1UBE2NTSHR | |
| SCHEMBL23394687 | 0.77 | CHRM5 (0.36) | KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL21036085 | 0.77 | SIGMAR1 (0.37) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425218-B2 | Nitric oxide-releasing medical devices | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1666047-A1 | Pharmaceutical compositions comprising nitric oxide-releasing pyrrolidones | The Government of the United States of America As represented by the Secretary of the Department Of Health and Human Services (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-0793500-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITRIC OXIDE-RELEASING POLYSACCHARIDES | US GOV HEALTH & HUMAN SERV (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20020119115-A1 | Nitric oxide-releasing medical devices | OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH (US) | 2002-08-29 | — | — | US | disclosed |
| US-6379660-B1 | BIOPOLYMERS; ADMINISTERING THERAPY DOSAGE; ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-04-30 | — | — | US | disclosed |
| US-6200558-B1 | PEPTIDE, POLYPEPTIDE, PROTEIN, OLIGONUCLEOTIDE OR NUCLEIC ACID, TO WHICH IS BOUND A NITRIC OXIDE-RELEASING N2O2-FUNCTIONAL GROUP | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-03-13 | — | — | US | disclosed |
| US-5721365-A | N-substituted piperazine NONOates | HEALTH AND HUMAN SERVICES, DEPARTMENT OF, UNITED STATES, AS REPRESENTED BY ITS SECRETARY | 1998-02-24 | — | — | US | disclosed |
| US-5700830-A | Use of nitric oxide-releasing agents for reducing metastasis risk | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-12-23 | — | — | US | disclosed |
| EP-0804177-A1 | USE OF NITRIC OXIDE-RELEASING AGENTS FOR REDUCING METASTASIS RISK | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5632981-A | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-05-27 | — | — | US | disclosed |
| WO-1996015781-A1 | USE OF NITRIC OXIDE-RELEASING AGENTS FOR REDUCING METASTASIS RISK | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119115-A1 | Nitric oxide-releasing medical devices | NOS2, NOS1, NOS3 | PPID 2360/4885NPC1 4318/4885CCR1 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.